201 related articles for article (PubMed ID: 28096506)
21. Antibody-mediated targeting of TNFR2 activates CD8
Tam EM; Fulton RB; Sampson JF; Muda M; Camblin A; Richards J; Koshkaryev A; Tang J; Kurella V; Jiao Y; Xu L; Zhang K; Kohli N; Luus L; Hutto E; Kumar S; Lulo J; Paragas V; Wong C; Suchy J; Grabow S; Dugast AS; Zhang H; Depis F; Feau S; Jakubowski A; Qiao W; Craig G; Razlog M; Qiu J; Zhou Y; Marks JD; Croft M; Drummond DC; Raue A
Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578241
[TBL] [Abstract][Full Text] [Related]
22. Bivalent structure of a TNFR2-selective and agonistic TNF-α mutein Fc-fusion protein enhances the expansion activity of regulatory T cells.
Inoue M; Tsuji Y; Ueno R; Miyamoto D; Tanaka K; Moriyasu Y; Shibata S; Okuda M; Ando D; Abe Y; Kamada H; Tsunoda SI
Sci Rep; 2023 Aug; 13(1):13762. PubMed ID: 37612373
[TBL] [Abstract][Full Text] [Related]
23. An immunocytokine consisting of a TNFR2 agonist and TNFR2 scFv enhances the expansion of regulatory T cells through TNFR2 clustering.
Inoue M; Tsuji Y; Kashiwada A; Yokoyama A; Iwata A; Abe Y; Kamada H; Tsunoda SI
Biochem Biophys Res Commun; 2024 Feb; 697():149498. PubMed ID: 38262291
[TBL] [Abstract][Full Text] [Related]
24. TNFR2 pathways are fully active in cancer regulatory T cells.
Okuzono Y; Muraki Y; Sato S
Biosci Biotechnol Biochem; 2022 Feb; 86(3):351-361. PubMed ID: 35015831
[TBL] [Abstract][Full Text] [Related]
25. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
[TBL] [Abstract][Full Text] [Related]
26. TNFR2: Role in Cancer Immunology and Immunotherapy.
Yang Y; Islam MS; Hu Y; Chen X
Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
[TBL] [Abstract][Full Text] [Related]
27. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
[TBL] [Abstract][Full Text] [Related]
28. Targeting TNFR2 in Cancer: All Roads Lead to Rome.
Bai J; Ding B; Li H
Front Immunol; 2022; 13():844931. PubMed ID: 35251045
[TBL] [Abstract][Full Text] [Related]
29. Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer.
Fu Q; Shen Q; Tong J; Huang L; Cheng Y; Zhong W
Front Cell Dev Biol; 2021; 9():720472. PubMed ID: 34900985
[TBL] [Abstract][Full Text] [Related]
30. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a TNFR2-Selective Agonistic TNF-α Mutant and Its Derivatives as an Optimal Regulatory T Cell Expander.
Inoue M; Yamashita K; Tsuji Y; Miki M; Amano S; Okumura T; Kuge K; Tone T; Enomoto S; Yoshimine C; Morita Y; Ando D; Kamada H; Mikami N; Tsutsumi Y; Tsunoda SI
J Immunol; 2021 Apr; 206(8):1740-1751. PubMed ID: 33782090
[TBL] [Abstract][Full Text] [Related]
32. Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: relation to inflammation, glycemic control and micro-vascular complications.
El-Samahy MH; Adly AA; Ismail EA; Salah NY
J Diabetes Complications; 2015; 29(1):120-6. PubMed ID: 25113439
[TBL] [Abstract][Full Text] [Related]
33. Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model.
Jing Q; Wan Q; Nie Y; Luo J; Zhang X; Zhu L; Gui H; Li L; Wang C; Chen S; Wang M; Yuan H; Lv H; Pan R; Jing Q; Nie Y
Front Pharmacol; 2023; 14():1286061. PubMed ID: 38161697
[No Abstract] [Full Text] [Related]
34. The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4
He T; Liu S; Chen S; Ye J; Wu X; Bian Z; Chen X
Front Immunol; 2018; 9():1556. PubMed ID: 30038619
[TBL] [Abstract][Full Text] [Related]
35. A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells.
He X; Landman S; Bauland SC; van den Dolder J; Koenen HJ; Joosten I
PLoS One; 2016; 11(5):e0156311. PubMed ID: 27224512
[TBL] [Abstract][Full Text] [Related]
36. TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.
Quazi S
Med Oncol; 2022 Sep; 39(12):215. PubMed ID: 36175687
[TBL] [Abstract][Full Text] [Related]
37. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.
Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z
J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122
[TBL] [Abstract][Full Text] [Related]
38. The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.
Moatti A; Cohen JL
Front Cell Dev Biol; 2021; 9():725473. PubMed ID: 34712661
[TBL] [Abstract][Full Text] [Related]
39. The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.
Takahashi H; Yoshimatsu G; Faustman DL
Cells; 2022 Jun; 11(12):. PubMed ID: 35741080
[TBL] [Abstract][Full Text] [Related]
40. Recombinant expression, purification and characterization of human soluble tumor necrosis factor receptor 2.
Li A; Sun K; Wang J; Wang S; Zhao X; Liu R; Lu Y
Protein Expr Purif; 2021 Jun; 182():105857. PubMed ID: 33639277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
